Atypical patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in patients with chronic myeloid leukemia

Similar documents
Role of FISH in Hematological Cancers

Patterns of BCR/ABL Gene Rearrangements by Fluorescence in Situ Hybridization (FISH) in Chronic Myeloid Leukaemia

Detection of abl/bcr Fusion Gene in Patients Affected by Chronic Myeloid Leukaemia by Dual-Colour Interphase Fluorescence in situ Hybridisation

Detection of derivative 9 deletion by BCR-ABL fluorescence in-situ hybridization signal pattern to evaluate treatment response in CML patients

Chronic myeloid leukemia (CML)

Fluorescence in-situ Hybridization (FISH) A Rapid and Useful Technique for Diagnosis and Management in Leukemia

Fluorescence in-situ Hybridization (FISH) ETO(RUNX1T1)/AML1(RUNX1) or t(8;21)(q21.3;q22)

BLOOD RESEARCH ORIGINAL ARTICLE INTRODUCTION

Reporting cytogenetics Can it make sense? Daniel Weisdorf MD University of Minnesota

Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML

Canadian College of Medical Geneticists (CCMG) Cytogenetics Examination. May 4, 2010

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Significance of Chromosome Changes in Hematological Disorders and Solid Tumors

Fluorescent in situ hybridization studies in multiple myeloma

Cytogenetic response to imatinib treatment in Southern Brazilian patients with chronic myelogenous leukemia and variant Philadelphia chromosome

BHS training course. Laboratory Hematology Cytogenetics. Lucienne Michaux. Centrum voor Menselijke Erfelijkheid, UZLeuven

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)

Hematopathology Case Study

CYTOGENETICS Dr. Mary Ann Perle

Applications of Fluorescence in Situ Hybridization (FISH) for Detecting Genetic Changes in Hematological Malignancies

An International System for Human Cytogenetic Nomenclature (2013)

Acute Promyelocytic Leukemia with i(17)(q10)

Oncology Genetics: Cytogenetics and FISH 17/09/2014

( Compauson of the JJsefulness_and_CoSts of R.r.AhI Analysis yprcnc. Chromosome Analyse

MULTIPLE GENETIC TESTING methods are used in

Peripheral Blood Monitoring of Chronic Myeloid Leukemia During Treatment With Imatinib, Second-Line Agents, and Beyond

Volume 7, Issue 1 January 2012

Research Article FISH Detection of PML-RARA Fusion in ins(15;17) Acute Promyelocytic Leukaemia Depends on Probe Size

MRD in CML (BCR-ABL1)

ONE STEP MULTIPLEX RT-PCR FOR BCRlABL GENE IN MALAY PATIENTS DIAGNOSED AS LEUKAEMIA

Understanding the Human Karyotype Colleen Jackson Cook, Ph.D.

CYTOGENETICS INTRODUCTION SPECIAL INSTRUCTIONS ON SAMPLE COLLECTION AND HANDLING

A novel five-way translocation t(7;11;9;22;9)(q22; q13;q34;q11.2;q34) involving Ph chromosome in a patient of chronic myeloid leukemia: a case report

Cytogenetic analyses in malignant hematological disorders

Fluorescent In-Situ Hybridization is the Hand Mirror of Cytogenetics: A Rare Case of Near Tetraploidy in Pediatric Acute Lymphoblastic Leukemia

Outline. Chromosomal analysis FISH. Chromosomal abnormalities in cancer. Clinical application of cytogenetics. Procedure Nomenclature

Hematopathology Case Study

DETERMINANT VALUE OF THE CYTOGENETIC AND MOLECULAR IMATINIB THERAPEUTIC RESPONSE IN CHRONIC MYELOID LEUKEMIA

Clinical utility of FISH analysis in addition to G-banded karyotype in hematologic malignancies and proposal of a practical approach

CML CML CML. tyrosine kinase inhibitor CML. 22 t(9;22)(q34;q11) chronic myeloid leukemia CML ABL. BCR-ABL c- imatinib mesylate CML CML BCR-ABL

Chronic myelogenous leukemia (CML) is a slowprogressing

Chronic Myeloid Leukaemia

Blast Phase Chronic Myelogenous Leukemia

"Molecular Monitoring Strategies to Track Response to BCR-ABL Kinase Inhibitors in CML"

An Overview of Cytogenetics. Bridget Herschap, M.D. 9/23/2013

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

Test Name Results Units Bio. Ref. Interval. Positive

FISH VALIDATION: HOW I DO IT!

Hematologic and cytogenetic responses of Imatinib Mesylate and significance of Sokal score in chronic myeloid leukemia patients

Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic

Identification of PML/RARα fusion gene transcripts that showed no t(15;17) with conventional karyotyping and fluorescent in situ hybridization

Addressing the challenges of genomic characterization of hematologic malignancies using microarrays

HEMATOPATHOLOGY SUMMARY REPORT RL;MMR;

Myelodysplastic Syndrome Case 158

Chromosomal Aberrations

Diagnostic challenge: Acute leukemia with biphenotypic blasts and BCR-ABL1 translocation

Acute Lymphoblastic Leukemia with Hyperdiploidy and Philadelphia Chromosome Poor or Good Prognostic Indicator?

CLL Complete SM Report

Integrated Diagnostic Approach to the Classification of Myeloid Neoplasms. Daniel A. Arber, MD Stanford University

MP BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Open Access Original Article

How I treat high risck CML

Test Name Results Units Bio. Ref. Interval. Positive

Diagnosis. Chapter 2. Diagnostic laboratory tests. Blood picture and biochemistry. Bone marrow morphology

KEY WORDS Chronic myelogenous leukemia Hematopoietic stem cell transplantation Relapse Imatinib mesylate Minimal residual disease

Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting (SIMPLICITY)

Objectives. Morphology and IHC. Flow and Cyto FISH. Testing for Heme Malignancies 3/20/2013

Cytogendies, in situ Hybridization and Molecular Approaches in the Diagnosis of Cancer*

Case Report RCSD1-ABL1 Translocation Associated with IKZF1 Gene Deletion in B-Cell Acute Lymphoblastic Leukemia

MPL W515L K mutation

Special Article. Introduction. Description of the method used to gather evidence: Aims. What are the diagnostic criteria for Chronic myeloid leukemia?

Reverse Transcriptase-Polymerase Chain Reaction for bcr/abl Fusion in Chronic Myelogenous Leukemia

ADx Bone Marrow Report. Patient Information Referring Physician Specimen Information

Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in a hospital in Brazil

JAK2 V617F analysis. Indication: monitoring of therapy

Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1+)

Title. CitationAnnals of Hematology, 82(9): Issue Date Doc URL. Rights. Type. File Information. major BCR/ABL

Case #1. 65 yo man with no prior history presented with leukocytosis and circulating blasts: Bone marrow biopsy was performed

2011: ALL Pre-HCT. Subsequent Transplant

Case Report Extra Copies of der(21)t(12;21) plus Deletion of ETV6 Gene due to dic(12;18) in B-Cell Precursor ALL with Poor Outcome

Cancer Biology 2016;6(1) Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia patients in Upper Egypt. Mervat M.

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.

ACMG/CAP Cytogenetics CY

Therapy-related MDS/AML with KMT2A (MLL) Rearrangement Following Therapy for APL Case 0328

Conventional Cytogenetics and Fluorescence In Situ Hybridization in Persistent Cytopenias and Myelodysplastic Syndromes in Childhood

35 Current Trends in the

How to detect the rare BCR ABL (e14a3) transcript: A case report and literature review

Research Article The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation

CYTOGENETIC STUDY OF 50 DE NOVO CASES OF ANLL FROM ARGENTINA. Susana Acevedo, Irma Slavutsky, Gabriela Andreoli, Irene Larripa

Chronic Myelogenous Leukemia with e13a3 (b2a3) Type of BCR-ABL Transcript Having a DNA Breakpoint between ABL exons a2 and a3

Talpaz M. et al. Dasatinib in Imatinib-resistant Philadelphia chromosomepositive leukemias. N Engl J Med (2006) 354;24:

STUDY OF CYTOGENETIC ABNORMALITIES IN G-CSF STIMULATED PERIPHERAL BLOOD CELLS AND NON-STIMULATED BONE MARROW CELLS OF PATIENTS WITH MYELOFIBROSIS

Current Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center

An update on imatinib mesylate therapy in chronic myeloid leukaemia patients in a teaching hospital in Malaysia

Revista Română de Medicină de Laborator Vol. 19, Nr. 3/4, Septembrie

Electroencephalography (EEG) alteration in Autism Spectum Disorder (ASD)

Haematology Probes for Multiple Myeloma

Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.

Transcription:

255 Original article Atypical patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in patients with chronic myeloid leukemia PrezenŃa unor aspecte atipice ale genei BCR/ABL puse în evidenńă prin FISH la pacienńii cu leucemie mieloidă cronică Cerasela Jardan 1*, Dumitru Jardan 1, Daniel Coriu 2, Emilia Severin 1 1. Carol Davila University of Medicine and Pharmacy Bucharest, Romania 2. Carol Davila University of Medicine and Pharmacy Bucharest, Romania; Fundeni Clinical Institute, Bucharest, Romania Abstract Fluorescent in situ hybridization (FISH) technique is increasingly used for the identification of BCR/ABL gene rearrangements in chronic myeloid leukemia (CML).Patients and Methods: Both typical and atypical pattern of BCR/ABL gene rearrangements was determined in 83 patients with CML referred to Fundeni Clinical Institute using dual fusion fluorescence in situ hybridization (DF-FISH) probes and conventional cytogenetics.results: in the majority of cases - 82 out of 83- CML patients exhibited a translocation between chromosome 9 and 22, resulting in a Philadelphia chromosome and one patient, negative for the Ph chromosome, presented cryptic BCR/ABL rearrangement. All samples were analyzed both by FISH and conventional cytogenetics. In 71 out of 83 cases the typical interphase FISH signal patterns of BCR/ABL gene rearrangements was identified one red signal, one green signal and two fusion signals (1R1G2F). The rest of 11 patients presented an atypical interphase FISH pattern. Atypical patterns included: loss of terminal region of derivative chromosome 9 (five patients), loss of derivative chromosome 9 (del(9q)der) (three patients), isodicentric 22 derivative chromosome fused at terminal region of q arm (one patient), isoderivative chromosomes 22 (ider(22)t(9;22) (q34;q11)) (one patient) and supernumerary Philadelphia (one patient).conclusion: FISH technique exhibited an advantage of being simple and still allowing the identification of cryptic BCR-ABL insertion or variant Ph. Another advantage of this technique is that it allows examination of interphase nuclei in cases were no metaphases could be obtained and atypical patterns may have clinical prognostic implication. Rezumat Keywords: peripheral blood-fish technique, BCR/ABL gene fusion, minimal residual disease Tehnica FISH este din ce in ce mai frecvent utilizată în identificarea rearanjărilor genei BCR/ABL la pacienńii cu leucemie mieloidă cronică. PacienƋi şi Metode: Determinarea aspecte tipice şi atipice ale genei * Corresponding author:cerasela Jardan, Adress: Departament of Hematology, Fundeni Clinical Institute, Sos. Fundeni 258, Sector 2, Bucharest, Romania, Tel: 0723636924, Email: cerasela.jardan@gmail.com

256 Revista Română de Medicină de Laborator Vol. 20, Nr. 3/4, Septembrie 2012 BCR/ABL a fost realizata la un numar de 83 de pacienńi internańi in Institutul Clinic Fundeni utilizând atât prin tehnica FISH (sonde FISH cu 2 semnale de fuziune) cât şi prin citogenetica conventională. Rezultate: Au fost investigańi prin examen citogenetic si tehnica FISH 83 de pacienńi. Cu excepńia unui singur pacient diagnosticat Philadelphia-negativ prin citogenetica conventională (cu rearanjare criptică a genei BCR/ABL pusa in evidenta prin tehnica FISH), restul de 82 au prezentat translocańia (9;22) (cromozomul Philadelphia). Dintre aceştia, 71 de pacienńi au avut un aspect tipic al genei de fuziune BCR/ABL (exprimat prin prezenta unui semnal rosu (cromozomul 9), unui semnal verde (cromozomul 22) si a doua semnale galbene rezultat din fuziunea celor doua gene de la nivelul cromozomilor 9 si 22) 1R1V2F iar 11 pacienńi au prezentat un aspect atipic. Aspectele atipice puse în evidenńă au prezentat: pierderea regiunii terminale a cromozomului 9 derivativ (del(9q)der) (cinci pacienti), pierderea cromozomului 9 derivativ (trei pacienti), cromozom 22 derivativ isodicentric (un pacient), cromozom 22 isoderivativ (ider(22)t(9;22)(q34;q11)) (un pacient) si Ph supranumerar (un pacient). Concluzii: Tehnica FISH are avantajul că este o tehnică simplă şi că permite punerea în evidenńă a rearanjărilor criptice ale genei BCR/ABL. Aspectele atipice puse în evidenńă prin această tehnică sunt utile în clinică pentru prognostic. Examinarea nucleilor interfazici în cazurile la care nu sunt obńinute metafaze reprezintă un avantaj în plus al tehnicii FISH. Cuvinte cheie: boală minimaă reyiduală, fuyiunea genelor BCR/ABL, tehnica FISH din sâange ăperferic Introduction Cytogenetic analysis is a standard method for chronic myeloid leukemia (CML) diagnosis. This method is especially useful as it not only identifies the landmark sign of CML Philadelphia (Ph) chromosome, but also allows identification of additional karyotype abnormalities. In 95% of CML cases at diagnosis, standard cytogenetics identifies a Ph chromosome which bears BCR- ABL1 fusion gene (1-4). In the remaining 5% of the cases no Ph chromosome could be detected. In these cases CML patients carry a cryptic translocation detectable by molecular techniques such as FISH or PCR (Polymerase Chain Reaction) (5). FISH analysis is important as an ancillary technique for CML evaluation, in combination with standard cytogenetics, as it identifies cryptic translocations and also displays a higher level of sensitivity in case of monitoring of minimal residual disease (MRD). Also, FISH technique is useful in cases where no metaphases can be obtained, as it allows examination of interphase nuclei. Initially, single fusion FISH probes were described which allowed identification of fusion event between BCR and ABL1 genes. Fusion is identified as a yellow signal which results from partial overlap of green and red fluorescence. Unfortunately, these probes displayed a high level of false positive results due to overlap of probes in nuclei. False positive rate was around 15% which was considered unacceptable especially for MRD evaluation (6). Thus technical artifacts limited the potential of single fusion FISH probes to detect and quantify minimal residual disease accurately. Dual fusion FISH probes were introduced to overcome technical limitations of single fusion ones. These probes are made so that each probe (on 9q and 22q) span the breakpoint region, so that translocation (9;22) generates two fusion gene signals: one on the Ph chromosome and one on the 9 th derivative chromosome. This improvement of FISH probes allows identification of Ph chromosomes with high level of confidence generally reducing level of false positives to almost nothing (7). Additional chromosome abnormalities in CML can cause disruption of a typical CML FISH pattern: one red, one green and two fusion signals (8, 9). In this article we describe abnormal FISH patterns identified in CML patients which were confirmed and explained by standard cytogenetics as additional chromosome abnormalities. Patients and methods A total of 83 patients referred to Fundeni Clinical Institute were included in the study. A

257 Figure 1. A. Karyotype 46,XY,t(9;22); B. A normal cell with two clearly separated Green (BCR probe) and Red (ABL probe) signals; C. Ph-positive cell with one Red signals, one Green signal, and two Yellow signal number of 21 samples derived from patients at the onset of the disease and 62 samples derived from patients during the course of therapy. In all cases, heparin-anticoagulation fresh bone marrow (BM) aspirate samples were obtained and used for the cytogenetic examination and FISH analysis. Conventional Karyotyping Bone marrow samples were cultured using overnight and synchronized culture and processed by conventional cytogenetic procedures with GTG banding (G-bands by trypsin and Giemsa) (10). In each case, at least 20 metaphases were analyzed and the karyotypes were described according to ISCN 2009 (11). FISH Analysis FISH analysis was performed on metaphases and interphase cells using a dual-color BCR/ABL probe, provided by Cytocell, Cambridge, UK. After slide preparation, cells were aged by incubation overnight at 37 C. FISH analysis of cultured BM samples was performed using slides obtained by usual protocol for cytogenetic examination. Slides were dehydrated in an alcohol series. Co-denaturation was carried out for 2 minutes at 75 C, followed by overnight hybridization at 37 C. After overnight hybridization slides were washed in 0,4X SSC at 73 C for 2 minutes and rinsed in 2 X SSC. Evaluation of the FISH signals was performed using a fluorescence microscope (AxioImager, Zeiss, Germany). For each case, a minimum of 200 interphase nuclei was evaluated. Results Evaluation of samples using conventional cytogenetics from 83 CML patients showed that in 82 cases a translocation between chromosome 9 and 22, resulting in a Philadelphia chromosome, was identified. Only one patient was negative for the Ph chromosome but positive for

258 Revista Română de Medicină de Laborator Vol. 20, Nr. 3/4, Septembrie 2012 Table 1. Atypical ifish patterns in Ph positive patients FISH pattern with Chromosome localisation of signals DF-FISH probes Fusion Red Green Interpretation 1F1R1G 1F(Ph) 1R(9) 1G(22) t(9;22) loss of residual proximal 9q 3R2G/1F 1R1G 1F(Ph) R(9) G(22) Trisomy 9; loss of residual proximal 9q 3F1R1G 3F(Ph,Ph,der9) R(9) G(22) t(9;22);+ph 5F1R1G 5F(der9;2ider22) R(9) G(22) der(9); 2ider(22)t(9;22)(q34;q11) 3F1R1G 3F(der9;idic(22)) R(9) G(22) der(9); idic(22)t(9;22)(q34;q11) ider: iso derivative; idic: iso dicentric; Ph: Philadelphia; F: fusion; R: red; G: green Figure 2. A. Karyotype 48,XX,+8,+9; B. A cell with two clearly separated Green (BCR probe) and three Red (ABL probe) signals; C. Cell with nuc ish (CEP8 x 3) BCR/ABL fusion gene identified by interphase FISH and confirmed by RT-PCR (Reverse transcription polymerase chain reaction). The majority of patients who exhibited Ph chromosome (71 out of 83) displayed the typical interphase FISH signal patterns of BCR/ABL gene rearrangements - 1R1G2F. Normal FISH pattern was confirmed by standard cytogenetics (except for the cryptic insertion) (Figure 1). In the rest of 11 patients atypical interphase FISH patterns were observed. Table 1 shows the types of atypical interphase FISH patterns in Ph positive patients. The first patient exhibited two abnormal interphase FISH patterns - 3R2G and

259 Figure 3. A. Karyotype 47,XY,der(9),2ider(22)t(9;22)(q34;q11) B. A cell with one Green signal (BCR probe, ch 22) and one Red (ABL probe,ch 9) signals and 5 Fusion signals. 1R1G1F. Cytogenetic evaluation revealed two cell lines one with trisomy 9, trisomy 8 and without Ph chromosome and the other with Ph chromosome and absence of derivative chromosome 9. Trisomy 8 was also confirmed by FISH analysis (Figure 2). The second patient exhibited 1R1G5F FISH pattern which corresponded to 47, XY, der(9),2 ider(22)t(9;22)(q34;q11) karyotype; 4 out of 5 fusion signals are due to two iso derivative 22 chromosome (the fifth fusion is due to derivative chromosome 9) (Figure 3). The third patient exhibited 1R1G3F FISH pattern. This pattern corresponded to 46,XX, der(9), idic(22)t(9;22)(q43;q11); 2 out of 3 fusion signals are due to iso dicentric derivative 22 chromosome fused at terminal region of q arm. The third fusion signal is due to derivative chromosome 9 (Figure 4). The fourth patient exhibited 1R1G3F FISH pattern which was explained by an additional Ph chromosome 47,XY, t(9;22), +Ph (Figure 5). In five patients 1F1R1G FISH (Figure 6) pattern was observed which was due to the loss of terminal region of derivative chromosome 9 46,XY/XX, t(9;22), del(9q?). In another two patients 1F1R1G FISH pattern was identified, this pattern was ex-

260 Revista Română de Medicină de Laborator Vol. 20, Nr. 3/4, Septembrie 2012 Figure 4. A. Karyotype 46,XX,der(9),idic(22)t(9;22)(q43;q11); B. A cell with one Green signal (BCR probe, ch 22) and one Red (ABL probe,ch 9) signals and 3 Fusion signals. plained by the loss of derivative chromosome 9-45,XY/XX, t(9;22), -der(9) (Figure 6). Discussions The present study shows that in the most of the cases expected FISH pattern (1R1G2F) corresponded to a typical Ph chromosome as confirmed by conventional cytogenetics. To this pattern one exception, namely a cryptic BCR- ABL insertion, was noticed. Thus, the utility of double fusion FISH for CML diagnostic and monitoring was shown to be important (12). On the other hand FISH technique exhibited an advantage of being simple and rapid and allowed for the identification of cryptic BCR-ABL insertion, which is not detectable by cytogenetics. Another advantage of this technique is that it allows examination of interphase nuclei in cases were no metaphases could be obtained. In a small fraction of patients (11 out of 83) dual fusion FISH probes generated atypical patterns as also described in the literature (8,12-14). These atypical signals were confirmed and explained by cytogenetics. In these cases additional cytogenetic changes present as aberrant pat-

261 Figure 5. A. Karyotype 47,XY,t(9;22),+Ph; B. A cell with one Green signal (BCR probe, ch 22) and one Red (ABL probe,ch 9) signals and 3 Fusion signals. terns could potentially be misdiagnosed with interphase FISH alone or could be hard to interpret with FISH on metaphases. Metaphase analyses showed that in cases with atypical interphase FISH patterns presence of an additional Ph and deletions of 9q sequences proximal to the breakpoint or of the whole derivative chromosome 9, were the two most frequent underlying genetic aberrations (12,14). Deletions of the proximal region of 9q chromosome do not represent a marker for disease progression as they tend to be consistent throughout the course of the disease (15,16). On the other hand Quintas-Cardama et al. (17) suggests that patients treated with Imatinib-mesylate can overcome negative prognostic impact of deletions of 9q chromosome region. Gain of an additional Ph chromosome usually translated in the appearance of an additional fusion signal. Literature suggests that additional Ph chromosomes are one of the most common additional genetic abnormalities in CML (14). However, additional fusion signal could be interpreted as a gain of additional derivative chromosome 9, as fusion signal is present on both derivative chromosomes. Also an expected pattern of two fusion signals can be attributed to two Ph chromosomes coupled with the loss of derivative chromosome 9 or distal part of 9q (which is not a rare event) (12,13). Usually acquisition of an additional Ph chromosome is associated with blast crisis. Indeed, our patients was in blast crisis when FISH detected supernumerary Ph, idic(ph) and ider(ph).

262 Revista Română de Medicină de Laborator Vol. 20, Nr. 3/4, Septembrie 2012 Figure 6. A. Karyotype 45,XY,t(9,22), -9; B. A cell with one Green signal (BCR probe, ch 22) and one Red (ABL probe,ch 9) signals and one Fusion signal. In our group of patients, gain of an additional Ph chromosome translated in expected pattern of free fusion signals. In cases where an idic(22)t(9;22)(q34;q11) or two ider(22)t(9;22) (q34;q11) were present interphase FISH pattern was totally misleading and could be explained only by a combination of cytogenetics and metaphase FISH. Conclusions Our results indicate that interphase FISH can correctly diagnose most of Ph+ CML cases. In some rare cases exact interpretation of observed pattern requires the application of the probes on metaphases complemented with conventional cytogenetics. Acquisition of additional genetic abnormalities detected as atypical FISH pattern may have implications on clinical diagnosis and prognosis of CML patients. Abbreviations BM- Bone Marrow CML- Chronic Myeloid Leukemia DF-FISH- double fusion - Fluorescence In Situ Hybridization FISH- Fluorescence In Situ Hybridization GTG- G-bands by trypsin and Giemsa ISCN- International System for Human Cytogenetic Nomenclature Ider- iso derivative Idic- iso dicentric MRD- Minimal Residual Disease PCR- Polymerase Chain Reaction RT-PCR - Reverse Transcription Polymerase Chain

263 Reaction Ph chromosome Philadelphia chromosome R- red; G- green; F-fusion (V-verde) References 1. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290 293. 2. Bartram CR, Carbonell F. BCR rearrangement in Phnegative CML. Cancer Genet Cytogenet 1986; 21: 183 184. 3. Ganesan TS, Rassool F, Guo AP, Th ng KH, Dowding C, Hibbin JA et al. Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 1986; 68: 957 960. 4. Shtalrid M, Talpaz M, Blick M, Romero P, Kantarjian H, Taylor K et al. Philadelphia-negative chronic myelogenous leukemia with breakpoint cluster region rearrangement: molecular analysis, clinical characteristics, and response to therapy. J Clin Oncol 1988; 6: 1569 1575. 5. Melo JV. The molecular biology of chronic myeloid leukaemia. Leukemia 1996; 10:751 756. 6. Gozzetti A, Le Beau MM. Fluorescence in situ hybridization: uses and limitations. Semin Hematol 2000; 37(4):320 333. 7. Itoh T, Tamura S, Takemoto Y, Kakishita E. A cytogenetic and fluorescence in situ hybridization evaluation of interferon-alpha in the treatment of chronic myeloid leukemia. Int J Mol Med 1999; 4(6):659 663. 8. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000; 95: 738 743. 9. Dewald GW, Wyatt WA, Juneau AL, Carlson RO, Zinsmeister AR, Jalal SM. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood 1998; 91(9):3357 3365. 10. Swansbury J: Methods in Molecular Biology. Cancer Cytogenetics Methods and Protocols. Humana Press 2003;220: 43-56 11. Lisa G. Shaffer, Marilyn L. Slovak, Lynda J. Campbell. ISCN 2009: An International System for Human Cytogenetic Nomenclature (2009): Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S Karger: 2009 12. Lim TH, Tien SL, Lim P, Lim AS. The incidence and patterns of BCR/ABL rearrangements in chronic myeloid leukemia (CML) using fluorescence in situ hybridisation (FISH). Ann Acad Med Singapore. 2005 Oct;34(9):533-8 13. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G.et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001;128:114-9 14. Primo D, Tabernero MD, Rasillo A, Sayagués JM, Espinosa AB, Chillón MC et al. Patterns of BCR/ABL gene rearrangements by interphase fluorescence in situ hybridization (FISH) in BCR/ABL+ leukemias: incidence and underlying genetic abnormalities. Leukemia. 2003;17(6):1124-9 15. Reid AG, Huntly BJ, Grace C, Green AR, Nacheva EP. Survival implications of molecular heterogeneity in variant Philadelphia-positive chronic myeloid leukemia. Br J Haematol. 2003;121(3):419-27 16. Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S et al. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. J Clin Oncol. 2010;28(16):2748-54 17. Quintas-Cardama A, Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia. Blood. 2005;105(6):2281-6.